 | Up a level |
Koeberle, D; Dufour, Jean-François; Demeter, G; Li, Q; Ribi, K; Samaras, P; Saletti, P; Roth, A D; Horber, D; Bühlmann, Michael; Wagner, A D; Montemurro, M; Lakatos, G; Feilchenfeldt, J; Peck-Radosavljevic, M; Rauch, D; Tschanz, B; Bodoky, G; Swiss Group for Clinical Cancer, SAKK (2016). Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Annals of oncology, 27(5), pp. 856-861. Oxford University Press 10.1093/annonc/mdw054
Koeberle, D; Betticher, D C; von Moos, R; Dietrich, D; Brauchli, P; Baertschi, D; Matter, K; Winterhalder, R; Borner, M; Anchisi, S; Moosmann, P; Kollár, Attila; Saletti, P; Roth, A; Frueh, M; Kueng, M; Popescu, R A; Schacher, S; Hess, V and Herrmann, R (2015). Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Annals of oncology, 26(4), pp. 709-714. Oxford University Press 10.1093/annonc/mdv011
Borner, M; Koeberle, D; Von Moos, R; Saletti, P; Rauch, D; Hess, V; Trojan, A; Helbling, D; Pestalozzi, B; Caspar, C; Ruhstaller, T; Roth, A; Kappeler, A; Dietrich, D; Lanz, D; Mingrone, W (2008). Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Annals of oncology, 19(7), pp. 1288-92. Oxford: Oxford University Press 10.1093/annonc/mdn058
Herrmann, R; Bodoky, G; Ruhstaller, T; Glimelius, B; Bajetta, E; Schüller, J; Saletti, P; Bauer, J; Figer, A; Pestalozzi, B; Köhne, CH; Mingrone, W; Stemmer, SM; Tàmas, K; Kornek, GV; Koeberle, D; Cina, S; Bernhard, J; Dietrich, D; Scheithauer, W; ... (2007). Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. Journal of clinical oncology, 25(16), pp. 2212-7. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2006.09.0886
Klaeser, B; Wiederkehr, O; Koeberle, D; Mueller, A; Bubeck, B; Thüerlimann, B (2007). Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer. Annals of oncology, 18(8), pp. 1329-34. Oxford: Oxford University Press 10.1093/annonc/mdm139
Joerger, M; Metaxas, Y; Schmitt, AM; Koeberle, D; Zaman, K; Betticher, D; Mach, N; Renner, C; Mark, M; Petrausch, U; Caspar, C; Britschgi, C; Taverna, C; Zenger, F; Mingrone, W; Schulz, J; Kopp, C; Hayoz, S; Stathis, A and von Moos, R (2020). Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA) (Unpublished). In: Virtual ESMO 2020.
